Donor CHIP and Allogeneic HSCT Outcome

Recruiting

Brief Summary: Current data on the impact of donor CHIP on long-term recipient outcome remain largely speculative. Data on the impact of donor CHIP including on allograft function, immunologic dysfunction, graft versus host disease (GVHD), disease relapse and survival across various donor populations are scarce. This is a retrospective-prospective cohort study designed to determine the association between donor gene mutations and outcome following allogeneic HSCT.

Detailed Description: This is a single centre prospective and retrospective cohort study. This study involves allo-HSCT recipients and their donors at Queen Mary Hospital, Hong Kong. Information on the presence of gene mutations in donor peripheral blood or bone marrow sample; gene mutations in recipient peripheral blood or bone marrow post-allo-HSCT; and donor and recipient outcome will be collected in either prospective, partial-prospective/retrospective or retrospective manner. The information will be used to determine the association between the presence of clonal haematopoiesis in the donor and recipient outcome following allo-HSCT.

Data will be collected through routine clinical visits and/or reviewing medical records. Data will be collected at the time of peripheral blood stem cells (PBSC) or bone marrow stem cells donation, at the time of allo-HSCT, one month post-allo-HSCT and every 6 months thereafter until death/study termination.

Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.

Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing.

Recruitment & Eligibility

Inclusion Criteria

Adult aged 18 year or above
Donor and recipient of allo-HSCT
In prospective and partial prospective/retrospective case, subjects who have provided a signed written informed consent. In retrospective case, subjects who had provided a previously signed written informed consent on:
1. voluntary provision of clinical data, and
2. voluntary provision of archived/remaining specimens for genetic analysis, and
3. authorizing storage and usage of archived/remaining specimens for any further analysis

Exclusion Criteria

Autologous peripheral blood stem cells or bone marrow stem cell donors for autologous HSCT

Arm && Interventions

Group	Intervention	Description
Allogeneic HSCT recipients and donors	Next generation sequencing	-

Primary Outcome Measures

Name	Time	Method
Progression-free survival (PFS) of the recipient.	5 years	This is defined as the time (in months) from the date of allo-HSCT to relapse/progression (event), death, latest follow-up or study termination.
Overall survival (OS) of the recipient.	5 years	This is defined as the time (in months) from the date of allo-HSCT to death from any cause (event), latest follow-up (censor) or study termination.

Secondary Outcome Measures

Name	Time	Method
Leukemia of donor origin	5 years	The occurrence of donor cell derived MDS/AML in the recipient following allogeneic HSCT
Cardiac complications	5 years	The occurrence of arrthymias, pericardial disease, coronary artery disease, myocardial dysfunction, pulmonary hypertension
Pulmonary complications	5 years	The occurrence of bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia.
Acute and chronic GVHD	5 years	The occurrence of acute and/or chronic graft-versus-host disease

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial